Anti-diabetics and antimicrobials: Harmony of mutual interplay

Diabetes is one of the four major non-communicable diseases, and appointed by the world health organization as the seventh leading cause of death worldwide. The scientists have turned over every rock in the corners of medical sciences in order to come up with better understanding and hence more effective treatments of diabetes. The continuous research on the subject has elucidated the role of immune disorders and inflammation as definitive factors in the trajectory of diabetes, assuring that blood glucose adjustments would result in a relief in the systemic stress leading to minimizing inflammation. On a parallel basis, microbial infections usually take advantage of immunity disorders and propagate creating a pro-inflammatory environment, all of which can be reversed by antimicrobial treatment. Standing at the crossroads between diabetes, immunity and infection, we aim in this review at projecting the interplay between immunity and diabetes, shedding the light on the overlapping playgrounds for the activity of some antimicrobial and anti-diabetic agents. Furthermore, we focused on the anti-diabetic drugs that can confer antimicrobial or anti-virulence activities.

Automated summary

Recent research has highlighted the role of immune disorders and inflammation in the progression of diabetes, emphasizing the importance of blood glucose regulation in reducing systemic stress and inflammation. Additionally, microbial infections can exacerbate inflammation through immunity disorders, which can be reversed with antimicrobial treatment. This review focuses on the interactions between immunity, infection, and diabetes, and the potential benefits of anti-diabetic drugs with antimicrobial or anti-virulence properties.